AstraZeneca response to vaccine suspension in parts of Europe

AstraZeneca released an official response after a group of European countries announced a temporary hiatus in vaccine application for having recorded severe cases of thrombosis in patients who had been inoculated.

One of the alarming data so far has been that of a deceased person in Denmark for side effects.

“An analysis of our safety data from more than 10 million records showed no evidence of an increased risk of pulmonary embolism or deep vein thrombosis in any age group, sex, batch or in any particular country with the AstraZeneca COVID-19 vaccine, “AstraZeneca communicated in a text titled “Vaccination situation in Denmark”.

He added: “In fact, the observed number of this type of event is significantly less in vaccinated people than one would expect in the general population ”.

For its part, the European Medicines Agency (EMA) urged the countries of the bloc on Thursday to move forward with the application of the AstraZeneca vaccine, because “The benefits continue to outweigh the risks.”

The EMA statement followed the decision of Denmark, Iceland, Norway and Italy to suspend as a “precaution” the use of the vaccine developed by the University of Oxford, already recommended by the United Kingdom and France.

According to the EMA, they were only shown until last Tuesday 22 cases of thrombosis among the three million people vaccinated in the European Union (EU), as well as in Norway and Iceland, who participate in the common vaccine strategy.

Austria announced on Monday that it had stopped administering a batch of laboratory vaccines after the death of a 49-year-old nurse that she suffered from “serious bleeding problems” within days of receiving it.

Four other European countries – Estonia, Lithuania, Latvia and Luxembourg – immediately stopped vaccination with doses of this batch.

The truth is, the new controversy arose on the same day the EMA approved the single-dose injection of Johnson & johnson, the fourth after those of Pfizer / BioNTech, Moderna and AstraZeneca, they need two injections for the vaccination.

As reported Bugle, in Argentina, for the moment, there is no scientific evidence to justify a suspension.

“All these points are evaluated by the National Vaccination Commission (Conain) and they have not yet been issued. It will be ANMAT, the regulatory authority, which will determine a possible measure, ”Gabriel Battistela, Undersecretary of Primary, Outpatient and Community Care in Buenos Aires, told this newspaper, referring to the vaccine used in the city for vaccinate. people over 80 and residents of retirement homes.

For the country, so far, 580 thousand doses of Covishield / AstraZeneca have arrived and the same is expected for the next few days.

From April, in addition, the 22.4 million doses manufactured in Argentina and packaged in Mexico would begin to arrive in the country. This is what the government has announced and hopes to pass.

With international agencies

AFG